ISSCR News
Priorities for our Future
As I begin my term as President of the ISSCR, I am honored to serve this dynamic and forward-looking global community of stem cell researchers, clinicians, and innovators. This year marks the final phase of our 2022–2025 strategic framework, which has guided our efforts around four central goals.
In the year ahead, I intend not only to complete these goals but also to critically reflect on the progress we’ve made. What worked well? What challenges remain? And how can these insights guide our vision for the next strategic cycle? These four pillars remain deeply relevant and will continue to shape the ISSCR’s direction in the coming years.
The ISSCR and STEMCELL Technologies Partner to Launch Free, On-Demand Course on Standards for Human Stem Cell Use in Research
The International Society for Stem Cell Research (ISSCR) and STEMCELL Technologies are proud to announce a new partnership to produce a free, on-demand course for researchers seeking to incorporate the ISSCR Standards for Human Stem Cell Use in Research in their work.
The ISSCR Releases Targeted Update to the Guidelines for Stem Cell Research and Clinical Translation
The International Society for Stem Cell Research (ISSCR) released an update of its 2021 Guidelines for Stem Cell Research and Clinical Translation today. The targeted update addresses significant advances in the development and application of human stem cell-based embryo models (SCBEMs) and recommendations for research oversight outlined in a white paper from the ISSCR Embryo Models Working Group published in June.
Member Spotlight: Ru Gunawardane, PhD
I was always interested in understanding how cells go wrong in disease and I was excited by the ability to use iPSCs to really get at how "normal" cells make decisions about cell fate and function.
The ISSCR Responds to EMA’s Concept Paper on the Revision of Part IV Guidelines on GMP Specific to ATMPs
On 8 July 2025, the ISSCR submitted comments on the European Medicines Agency's concept paper on the revision of Part IV Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products. ISSCR supports the proposal to update t Part IV of the Guidelines to address inconsistencies, clarify ambiguities, and to include guidance on the use of new manufacturing technologies.
The ISSCR recommends incorporating these updates into the main body of EudraLex Volume 4, rather than maintaining them as a separate document. This approach would offer more consistent and clear guidance to ATMP developers.
To request the comments or learn more, contact Denise de Villa.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .